De Novo device
gammaCore Non-invasive Vagus Nerve Stimulator
Electrocore, LLC · Non-Invasive Vagus Nerve Stimulator - Headache (PKR, Class II) · First FDA decision Apr 14, 2017, newest Apr 14, 2017Migraine and headache
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
46
Naming "gammaCore"
MAUDE reports
1
Brand "gammaCore", since 2015
PubMed studies
120
Mentioning "gammaCore"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing gammaCore Non-invasive Vagus Nerve Stimulator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- gammaCore Non-invasive Vagus Nerve StimulatorNew device typeDe Novo
DEN150048 · Decided Apr 14, 2017 · 546 days after receipt
Device type: Non-Invasive Vagus Nerve Stimulator - Headache (PKR) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Vagus Nerve Stimulation (VNS)National determinationOn the books160.18Updated Nov 5, 2026
- Vagus Nerve Stimulation for Treatment of Resistant Depression (TRD)National analysisReview closedCAG-00313RUpdated Sep 24, 2026
- Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)National analysisReview closedCAG-00313R2Updated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "gammaCore", any status and sponsor, newest update first.
- Effects of nVNS on Stress Reactivity in IBSPivotal-lookingNot yet recruiting
University of California, Los AngelesAcademic, hospital or other
NCT07926945 · 200 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2031
Device: Truvaga Plus · For: Irritable Bowel Syndrome (IBS)
Sites: Los Angeles, California
45 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "gammaCore", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PKR
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
- GAMMACORE-S UNITInjury
3009060963-2018-00001 · Received Oct 24, 2018 · Event dated Sep 12, 2018
Device type: Non-Invasive Vagus Nerve Stimulator - Headache (PKR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Swollen Lymph Nodes; Twitching; Numbness; Ambulation or Postural Difficulties
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "gammaCore"[tiab]. The summary above synthesizes these.
- Drugs for migraine.
Med Lett Drugs Ther · 2023
- Drugs for Migraine.
Med Lett Drugs Ther · 2020
- Worms' Antimicrobial Peptides.
Bruno R, Maresca M, Canaan S, et al. · Mar Drugs · 2019Review
- gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance.
O'Connell S, Dale M, Morgan H, et al. · Pharmacoecon Open · 2021Review
- Cost-effectiveness of gammaCore (non-invasive vagus nerve stimulation) for acute treatment of episodic cluster headache.
Mwamburi M, Liebler EJ, Tenaglia AT · Am J Manag Care · 2017Multicenter Study, Randomized Controlled Trial
- International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.
Yuan H, Orr SL, Al-Karagholi MAM, et al. · Cephalalgia · 2025Systematic Review, Practice Guideline
- Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine: efficacy, safety, and implications.
Mwamburi M, Tenaglia AT, Leibler EJ, et al. · Am J Manag Care · 2018Research Support, Non-U.S. Gov't, Review
- Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies.
Mwamburi M, Tenaglia AT, Leibler EJ, et al. · Am J Manag Care · 2018Research Support, Non-U.S. Gov't
- Ixodes ricinus defensins attack distantly-related pathogens.
Tonk M, Cabezas-Cruz A, Valdés JJ, et al. · Dev Comp Immunol · 2015Research Support, Non-U.S. Gov't
- Patient experience with non-invasive vagus nerve stimulator: gammaCore patient registry.
Mwamburi M, Liebler EJ, Staats PS · Am J Manag Care · 2020Observational Study, Research Support, Non-U.S. Gov't
- Neurostimulation in the treatment of primary headaches.
Miller S, Sinclair AJ, Davies B, et al. · Pract Neurol · 2016Review
- Drugs for prevention of migraine.
Med Lett Drugs Ther · 2026
Other devices of this type
Also filed under product code PKR.
- gammaCore SapphireElectrocore, Inc. · 510(k) 2021
- gammaCore-SElectrocore, LLC · 510(k) 2018
- gammaCore-2Eletrocore, LLC · 510(k) 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.